Precision Antibody to Present Fully Human Monoclonal Antibody Research at AACR Annual Meeting 2026

COLUMBIA, Md. - April 16, 2026 - PRLog -- Columbia, MD—Precision Antibody is proud to announce its participation and scientific presentations at the AACR Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, California.

Hosted by the American Association for Cancer Research, the AACR Annual Meeting is one of the world's most prestigious cancer research conferences.

Precision Antibody will present two poster presentations highlighting its advancements in fully human monoclonal antibody development for oncology applications, including antibody-drug conjugates (ADCs). Notably, these fully human antibodies were developed in approximately 60 days, demonstrating the company's ability to accelerate discovery timelines without compromising quality.

Poster Presentation Details

Poster #1: Fully human monoclonal antibodies for ADC development to a cell surface target expressed in cancers with unmet needs

Date: April 19, 2026

Time: 2:00 – 5:00 PM

Abstract # 3613

Poster Section: 18

Board # 30

Poster #2: Title: Fully human anti-HER-2 antibodies with distinct epitopes as superior ADCs for tumor growth inhibition

Date: April 20, 2026

Time: 2:00 – 5:00 PM

Abstract # 3168

Poster Section: 19

Board # 3

These presentations underscore Precision Antibody's expertise in generating high-affinity, epitope-rich, and fully functional monoclonal antibodies designed to support next-generation cancer therapeutics and ADC development.

"We are excited to present our latest research at AACR 2026 and contribute to the advancement of oncology therapeutics," said Dr. Serrero. "Our ability to develop fully human monoclonal antibodies in as little as 60 days is helping accelerate drug discovery and enabling our partners to move faster toward clinical success."

As biomarker antibody specialists, Precision Antibody has a strong track record of developing high-quality biomarker antibodies for oncology research. The company is also a proud contributor to the National Cancer Institute's Clinical Proteomic Technologies for Cancer (CPTC) program through Leidos, helping establish gold-standard monoclonal antibodies widely used in cancer biomarker research.

Precision Antibody invites attendees of the AACR Annual Meeting 2026 to visit their poster sessions and connect with the team to learn more about their rapid, royalty-free fully human monoclonal antibody development platform.

About Precision Antibody

Founded in 2000, Precision Antibody is a U.S.-based biotechnology company specialising in the rapid development of custom monoclonal antibodies. With a proven track record in biomarker antibody development and contributions to the NCI's Clinical Proteomic Technologies for Cancer (CPTC) program, Precision Antibody is recognised for setting benchmarks in antibody quality and reliability. In 2025, the company was honoured as the Best Monoclonal Antibody Development Company, reinforcing its leadership and commitment to advancing diagnostics, therapeutics, and translational research through high-performance, royalty-free antibodies.

Website: www.precisionantibody.com